Toggle navigation
Home
Search
Services
Blog
Contact
About
OBl-1 - 201: Dosing regimen, cogential hemophilia, non-life threatening bleeding
Bergman, Garrett E.
Octagen Corporation, Blue Bell, PA, United States
Search 11 grants from Garrett Bergman
Search grants from Octagen Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Wake Forest NCORP Research Base
Reproducibility and Clinical Implications of Masked Hypertension
Nitric Oxide as a Modifier of Oxidative Stress
Multimodality Cancer Therapy Protocol
RAPID: Collaborative Research: Mobilization and transport of contaminants to groundwater in flood-impacted unconnected communities in South Texas following Hurricane Hanna
Recently added grants:
Endplate Sensory Innervations for LBP
PTH Attenuation of Spinal Degeneration During Aging PI Janet Crane
Senescence of Pre-Osteoclasts in Non-Traumatic OA
Modeling Photoreceptor Migration in Biomimetic Microenvironments to Optimize Transplantation
Linkage of s100a10 (p11) to enteric 5-HT4-mediated serotonergic signaling roles in GI motility, enteric nervous system development, and co-morbid dysfunction of gut and brain
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44HL064497-04
Application #
7149838
Study Section
Special Emphasis Panel (ZRG1)
Project Start
2005-08-01
Project End
2008-07-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2005
Total Cost
Indirect Cost
Institution
Name
Octagen Corporation
Department
Type
DUNS #
052982852
City
Blue Bell
State
PA
Country
United States
Zip Code
19422
Related projects
Comments
Be the first to comment on Garrett Bergman's grant